Skip to main content

Advertisement

SpringerLink
Log in

Adjuvant Therapy in Combination with Resection of Colorectal Cancer Metastasis to the Liver or Lungs

  • ADJUVANT THERAPY FOR COLON CANCERS (AB BENSON III AND A DE GRAMONT, SECTION EDITORS)
  • Published:
Current Colorectal Cancer Reports

Abstract

Surgical resection is associated with prolonged survival for patients with limited lung or liver metastatic colorectal cancer. The benefit of resection of colorectal liver metastases is widely accepted. However, after complete resection of colorectal liver metastases, up to 70 % of patients develop recurrence. Oncosurgical strategies, including complete resection and chemotherapy, have been developed to improve oncological outcome and to reduce recurrence after resection of colorectal liver metastases. Chemotherapy in combination with liver resection can be administered before, after, or before and after the surgical procedure. Perioperative chemotherapy has been revealed to reduce the risk of recurrence and has been accepted as a standard of care for patients with resectable liver metastases. Research, including intensification of chemotherapy administered in combination with surgery, is ongoing to further improve outcomes for patients with resectable liver metastases. There are currently few data regarding the benefit of chemotherapy administered in association with resection of lung metastases from colorectal cancer. A large prospective trial is currently evaluating the benefit of resection of lung metastases from colorectal cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.

    Article  PubMed  Google Scholar 

  2. Nordlinger B, Van Cutsem E, Gruenberger T, et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol. 2009;20:985–92.

    Article  CAS  PubMed  Google Scholar 

  3. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371:1007–16. This study is the first to validate the concept of multimodality treatment of resectable colorectal liver metastases.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Brouquet A, Vauthey JN, Contreras CM, et al. Improved survival after resection of liver and lung colorectal metastases compared with liver-only metastases: a study of 112 patients with limited lung metastatic disease. J Am Coll Surg. 2011;213:62–9.

    Article  PubMed  Google Scholar 

  5. Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25:1670–6.

    Article  CAS  PubMed  Google Scholar 

  6. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.

    Article  CAS  PubMed  Google Scholar 

  7. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408–17.

    Article  PubMed  Google Scholar 

  8. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009;27:663–71.

    Article  CAS  PubMed  Google Scholar 

  9. Adam R, Wicherts DA, de Haas RJ, et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol. 2009;27:1829–35. This study suggests that even patients who had initially unresectable liver metastases have a possibility of cure up to 20 % of the cases.

    Article  PubMed  Google Scholar 

  10. Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11:38–47. This prospective study validates the concept of conversion chemotherapy. Effective chemotherapy can make resectable lesions initially regarded as unresectable in case of good response.

    Article  CAS  PubMed  Google Scholar 

  11. Van Cutsem E, Köhne CH, Láng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29:2011–9.

    Article  PubMed  Google Scholar 

  12. Maughan TS, Adams RA, Smith CG, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet. 2011;377:2103–14.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28:4697–705.

    Article  CAS  PubMed  Google Scholar 

  14. Hurwitz HI, Yi J, Ince W, et al. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist. 2009;14:22–8.

    Article  CAS  PubMed  Google Scholar 

  15. Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013–9.

    Article  CAS  PubMed  Google Scholar 

  16. Okines A, Puerto OD, Cunningham D, et al. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer. 2009;101:1033–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Masi G, Loupakis F, Pollina L, et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg. 2009;249:420–5.

    Article  PubMed  Google Scholar 

  18. Ye LC, Liu TS, Ren L, et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol. 2013;31:1931–8.

    Article  CAS  PubMed  Google Scholar 

  19. Wong R, Cunningham D, Barbachano Y, et al. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol. 2011;22:2042–8.

    Article  CAS  PubMed  Google Scholar 

  20. Goéré D, Deshaies I, de Baere T, et al. Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases. Ann Surg. 2010;251:686–91.

    Article  PubMed  Google Scholar 

  21. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14:1208–15.

    Article  CAS  PubMed  Google Scholar 

  22. Hebbar M, Chibaudel B, Andre T, et al. FOLFOX4 (12 cycles) versus sequential dose-dense FOLFOX7 (6 cycles) followed by FOLFIRI (6 cycles) in patients with initially resectable metastatic colorectal cancer: a GERCOR randomized phase III study (MIROX). J Clin Oncol. 2012. (suppl; abstr 3506).

  23. Primrose JN, Falk S, Finch-Jones M, et al. A randomized clinical trial of chemotherapy compared to chemotherapy in combination with cetuximab in k-RAS wild-type patients with operable metastases from colorectal cancer: The new EPOC study. J Clin Oncol. 2013 (suppl; abstr 3504).

  24. Adam R, Bhangui P, Poston G, et al. Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases? Ann Surg. 2010;252:774–87.

    Article  PubMed  Google Scholar 

  25. Sorbye H, Mauer M, Gruenberger T, et al. Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). Ann Surg. 2012;255:534–9.

    Article  PubMed  Google Scholar 

  26. Portier G, Elias D, Bouche O, et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol. 2006;24:4976–82.

    Article  CAS  PubMed  Google Scholar 

  27. Langer B, Bleiberg H, Labianca R, et al. Fluorouracil (FU) plus leucovorin (I-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): results of the ENG (EORTC/NCIC CTG/GIVIO) randomized trial. Proc Am Soc Clin Oncol 2002;21:149a:[abstract 592]

  28. Mitry E, Fields AL, Bleiberg H, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol. 2008;26:4906–11.

    Article  CAS  PubMed  Google Scholar 

  29. Ychou M, Hohenberger W, Thezenas S, et al. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol. 2009;20:1964–70.

    Article  CAS  PubMed  Google Scholar 

  30. Nelson R, Freels S. Hepatic artery adjuvant chemotherapy for patients having resection or ablation of colorectal cancer metastatic to the liver. Cochrane Database Syst Rev. 2006;(4):CD003770. The results of this meta-analysis reveal that hepatic artery infusion cannot be recommended as a standard of care after resection of colorectal liver metastases.

  31. Alberts SR, Roh MS, Mahoney MR, et al. Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a north central cancer treatment group (NCCTG)/ national surgical adjuvant breast and bowel project (NSABP) phase II intergroup trial, N9945/CI-66. J Clin Oncol. 2010;28:853–8.

    Article  PubMed Central  PubMed  Google Scholar 

  32. Hebbar M, Chibaudel B, André T, et al. Randomized trial of simplified LV5FU2 versus FOLFOX7 followed by FOLFIRI (MIROX) in patients with initially resectable metastatic colorectal cancer: a GERCOR study. J Chemother. 2013;25:104–11.

    Article  CAS  PubMed  Google Scholar 

  33. Treasure T, Fallowfield L, Lees B. Pulmonary metastasectomy in colorectal cancer: the PulMiCC trial. J Thorac Oncol. 2010;5(6 Suppl 2):S203–6.

    Article  PubMed  Google Scholar 

  34. Brouquet A, Mortenson MM, Vauthey JN, et al. Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy? J Am Coll Surg. 2010;210:934–41.

    Article  PubMed  Google Scholar 

  35. Reddy SK, Pawlik TM, Zorzi D, et al. Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol. 2007;14:3481–91.

    Article  PubMed  Google Scholar 

  36. Andres A, Toso C, Adam R, et al. A survival analysis of the liver-first reversed management of advanced simultaneous colorectal liver metastases: a LiverMetSurvey-based study. Ann Surg. 2012;256:772–8.

    Article  PubMed  Google Scholar 

  37. Poultsides GA, Servais EL, Saltz LB, et al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol. 2009;27:3379–84.

    Article  PubMed Central  PubMed  Google Scholar 

  38. Adam R, Pascal G, Castaing D, et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg. 2004;240:1052–61.

    Article  PubMed Central  PubMed  Google Scholar 

  39. Benoist S, Brouquet A, Penna C, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol. 2006;24:3939–45.

    Article  PubMed  Google Scholar 

  40. Elias D, Goere D, Boige V, et al. Outcome of posthepatectomy-missing colorectal liver metastases after complete response to chemotherapy: impact of adjuvant intra-arterial hepatic oxaliplatin. Ann Surg Oncol. 2007;14:3188–94.

    Article  PubMed  Google Scholar 

  41. Auer RC, White RR, Kemeny NE, et al. Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy. Cancer. 2010;116:1502–9.

    Article  PubMed  Google Scholar 

  42. van Vledder MG, de Jong MC, et al. Disappearing colorectal liver metastases after chemotherapy: should we be concerned? J Gastrointest Surg. 2010;14:1691–700.

    Article  PubMed  Google Scholar 

  43. Zalinski S, Abdalla EK, Mahvash A, Vauthey JN. A marking technique for intraoperative localization of small liver metastases before systemic chemotherapy. Ann Surg Oncol. 2009;16:1208–11.

    Article  PubMed  Google Scholar 

  44. Tamandl D, Klinger M, Eipeldauer S, et al. Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. Ann Surg Oncol. 2011;18:421–30.

    Article  PubMed  Google Scholar 

  45. Hamady ZZ, Rees M, Welsh FK, et al. Fatty liver disease as a predictor of local recurrence following resection of colorectal liver metastases. Br J Surg. 2013;100:820–6.

    Article  CAS  PubMed  Google Scholar 

  46. Brouquet A, Nordlinger B. Metastatic colorectal cancer outcome and fatty liver disease. Nat Rev Gastroenterol Hepatol. 2013;10:266–7.

    Article  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Antoine Brouquet has received speaker’s honoraria from Merck-Serono, Amgen, and Roche. Bernard Nordlinger has received speaker’s honoraria from Roche, Amgen, Merck-Serono, and Sanofi-Aventis.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Service de Chirurgie Digestive et Oncologique, Hôpital Bicêtre, Assistance Publique, Hôpitaux de Paris, Université Paris Sud, Inserm U986, Paris, France

    Antoine Brouquet

  2. Service de Chirurgie Digestive et Oncologique, Hôpital Ambroise Paré, Assistance Publique, Hôpitaux de Paris, Paris, France

    Bernard Nordlinger

Authors
  1. Antoine Brouquet
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bernard Nordlinger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bernard Nordlinger.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Brouquet, A., Nordlinger, B. Adjuvant Therapy in Combination with Resection of Colorectal Cancer Metastasis to the Liver or Lungs. Curr Colorectal Cancer Rep 10, 354–361 (2014). https://doi.org/10.1007/s11888-014-0239-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11888-014-0239-0

Keywords

Search

Navigation